Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Date:9/21/2007

NEW YORK, Sept. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Michael P. Tarnok to the Company's Board of Directors.

Mr. Tarnok, 53, a seasoned finance and operational executive, joins the Keryx Board with extensive pharmaceutical industry experience in a wide range of functional areas. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director - US Manufacturing, and from 2000-2007, served as Senior Vice President, Finance in Pfizer's US Pharmaceuticals Division. In this position, Mr. Tarnok handled all finance responsibilities for the division, including Contracting, Trade management, forecasting of significant product launches and Sarbanes Oxley compliance. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and B.S. in Accounting from St. John's University.

"We are pleased that Mike has agreed to join the Keryx Board of Directors," stated Michael S. Weiss, Chairman and Chief Executive Officer of Keryx. Weiss continued, "Mike has extensive financial, operational and manufacturing experience in the pharmaceutical industry, and we are excited to have his broad experience in the boardroom as we plan for the launch of Sulonex(TM) and the transition from a development stage company into a commercial organization. Mike played a significant role in the rapid growth of Pfizer's U.S. Pharmaceutical division and his perspective and sense of scale will be invaluable as we continue to build Keryx into a leading biotechnology company."

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a ... Market for Liquid Biopsy is growing rapidly and expected to reach ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a swiftly ... figures and boom in the coming future. There has been a ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
Breaking Biology Technology:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):